Xue Xiujuan, Sun Guoqing, Liu Chunhua, Liu Jia, Tian Suian, Wang Zhe
Center for AIDS/STD Control and Prevention, Henan Center for Disease Control and Prevention, Zhengzhou 450016, China.
Center for AIDS/STD Control and Prevention, Henan Center for Disease Control and Prevention, Zhengzhou 450016, China. Email:
Zhonghua Yu Fang Yi Xue Za Zhi. 2014 Aug;48(8):684-7.
To explore the related testing indicators variation of HIV long-term non-progress populations.
The long-term non-progress populations in some areas of Henan were recruited, and the study was carried out according to different CD4(+)T lymphocytes counts for two groups. The dynamic characteristics of immune status and viral load between LTNP-1group (CD4(+)T lymphocytes ≥ 500/µl, 42 cases) and LTNP-2 group(350/µl ≤ CD4(+)T lymphocytes < 500/µl, 49 cases) from July 2010 to August 2013 were observed. The characteristics of HIV elite controllers during the follow-up were also described.
LTNP were recruited, 56% (51 cases) were men, and 44% (40 cases) were women. The study population were aged from 38 to 65 years old. A total of 320 individuals were followed-up, 14 cases were lost, 2 deaths, and 16 cases had received antiretroviral therapy during four years. To analyze the annual changes of CD4(+)T lymphocytes and VL of the group from 2010 to 2013, LTNP-1 group CD4(+)T lymphocytes from 654.0(545.2-809.5) decreased to 494.0(341.0-574.7), and LTNP-2 group decreased from 493.0 (429.5-770.0) to 343.5(253.0-500.8), CD4(+)T lymphocytes decline of over times of two groups in longitudinal analysis (χ(2) = 50.32, P < 0.01; χ(2) = 31.03, P < 0.01). lg (VL) of LTNP-1 group were 3.52 (3.15-4.27), 3.71 (2.70-4.55), 3.86 (3.59-4.55), 3.96 (3.25-4.36), and lg (VL) of TNP-2 group were 4.35 (3.72-4.83), 4.35 (3.97-4.94), 4.71 (3.96-4.95), 5.04(4.78-5.26), respectively (P > 0.05). The same year inter-group comparison found CD4(+)T lymphocytes of LTNP-1 group were higher than LTNP-2 group (Z = 5.23, P < 0.01; Z = 3.06, P < 0.01; Z = 2.51, P < 0.05; Z = 2.47, P < 0.05). VL of LTNP-2 group increased from 4.35(3.97-4.94) to 5.04 (4.78-5.26) during 2011 to 2013, were higher than LTNP-1 group in the same year (Z = 2.28, P < 0.05; Z = 2.58, P < 0.05; Z = 2.76, P < 0.05). 65 cases HCV antibody were positive in 91 individuals, and the HCV antibody positive rate was 76% (32/42), 67% (33/49) between LTNP-1 group and LTNP-2 group. Six elite controllers maintained CD4(+)T lymphocytes ≥ 500/µl, VL<1 000 copies/ml during four years follow-up.
The long-term non-progress populations in Henan were overall healthy, and VL were relatively stable, there was a decreased trend of CD4 year by year, and HCV co-infection rate was high.
探讨HIV长期不进展人群相关检测指标的变化情况。
招募河南部分地区的长期不进展人群，根据CD4(+)T淋巴细胞计数不同分为两组进行研究。观察2010年7月至2013年8月LTNP - 1组（CD4(+)T淋巴细胞≥500/µl，42例）和LTNP - 2组（350/µl≤CD4(+)T淋巴细胞＜500/µl，49例）免疫状态和病毒载量的动态变化特征。同时描述随访期间HIV精英控制者的特征。
共招募长期不进展者，56%（51例）为男性，44%（40例）为女性。研究人群年龄为38至65岁。共320人接受随访，4年中14例失访，2例死亡，16例接受过抗逆转录病毒治疗。分析2010至2013年两组人群CD4(+)T淋巴细胞和病毒载量的年度变化，LTNP - 1组CD4(+)T淋巴细胞从654.0(545.2 - 809.5)降至494.0(341.0 - 574.7)，LTNP - 2组从493.0(429.5 - 770.0)降至343.5(253.0 - 500.8)，两组CD4(+)T淋巴细胞纵向下降倍数差异有统计学意义（χ(2)=50.32，P＜0.01；χ(2)=31.03，P＜0.01）。LTNP - 1组lg（病毒载量）分别为3.52(3.15 - 4.27)、3.71(2.70 - 4.55)、3.86(3.59 - 4.55)、3.96(3.25 - 4.36)，LTNP - 2组lg（病毒载量）分别为4.35(3.72 - 4.83)、4.35(3.97 - 4.94)、4.71(3.96 - 4.95)、5.04(4.78 - 5.26)，差异无统计学意义（P＞0.05）。同年组间比较发现LTNP - 1组CD4(+)T淋巴细胞高于LTNP - 2组（Z = 5.23，P＜0.01；Z = 3.06，P＜0.01；Z = 2.51，P＜0.05；Z = 2.47，P＜0.05）。2011至2013年LTNP - 2组病毒载量从4.35(3.97 - 4.94)升至5.04(4.78 - 5.26)，同年高于LTNP - 1组（Z = 2.28，P＜0.05；Z = 2.58，P＜0.05；Z = 2.76，P＜0.05）。91人中65例HCV抗体阳性，LTNP - 1组和LTNP - 2组HCV抗体阳性率分别为76%（32/42）、67%（33/49）。6例精英控制者在4年随访期间CD4(+)T淋巴细胞≥500/µl，病毒载量＜1000拷贝/ml。
河南HIV长期不进展人群整体健康，病毒载量相对稳定，CD4逐年呈下降趋势，HCV合并感染率高。
